Drug Profile
Imeglimin - Poxel
Alternative Names: EMD-387008; Imeglimin hydrochloride - Poxel; PXL 008; RVT-1501; TWYMEEGLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Merck KGaA
- Developer Poxel; Sumitomo Pharma
- Class Amines; Antihyperglycaemics; Small molecules; Triazines; Urologics
- Mechanism of Action Insulin secretion stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Marketed Type 2 diabetes mellitus
- No development reported Kidney disorders
Most Recent Events
- 23 Mar 2023 Launched for Type 2 diabetes mellitus in India (PO), prior to March 2023
- 01 Apr 2022 Sumitomo Dainippon Pharma is now called Sumitomo Pharma
- 28 Dec 2021 No recent reports of development identified for phase-I development in Kidney-disorders(In the elderly, In adults) in Japan (PO, Tablet)